Valo Tx is an immunotherapy company that is developing antigen-coated oncolytic viruses and vaccine vectors as therapeutic vaccines against cancer and infectious diseases. Valo Tx’s lead platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. It turns oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without the need to develop and manufacture multiple genetically modified viruses.
“The investment in Valo demonstrates MMJ’s expertise to secure a private negotiated investment in unlisted businesses which are not generally available to Australian retail and institutional investors, Mr. Wall (MMJ’s Chairman) said. Valo represents the continued deployment of funds in accordance with its investment strategy following the broadening of MMJ’s investment mandate in 2020.”
A copy of Valo Tx’s announcement is attached to this release.
MMJ’s investment in Valo comprises convertible notes with an acquisition cost of AUD1m.